These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8570770)

  • 21. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.
    Tune LE; Creese I; Depaulo JR; Slavney PR; Coyle JT; Snyder SH
    Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
    Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
    Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Certain neuroleptics reduce bone mineralization in schizophrenic patients.
    Higuchi T; Komoda T; Sugishita M; Yamazaki J; Miura M; Sakagishi Y; Yamauchi T
    Neuropsychobiology; 1987; 18(4):185-8. PubMed ID: 2900482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.
    Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A
    Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of schizophrenia: what the family doctor should know].
    Gruber O; Falkai P
    MMW Fortschr Med; 2008 May; 150 Suppl 2():16-9; quiz 20. PubMed ID: 18680837
    [No Abstract]   [Full Text] [Related]  

  • 26. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication.
    Glovinsky D; Kalogeras KT; Kirch DG; Suddath R; Wyatt RJ
    Schizophr Res; 1994 Feb; 11(3):273-6. PubMed ID: 7910756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroleptic-free intervals in the treatment of schizophrenia.
    Pyke J; Seeman MV
    Am J Psychiatry; 1981 Dec; 138(12):1620-1. PubMed ID: 6118068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clozapine treatment after agranulocytosis induced by classic neuroleptics.
    Bauer M; Mackert A
    J Clin Psychopharmacol; 1994 Feb; 14(1):71-3. PubMed ID: 7908676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reducing the dose of depot neuroleptics in stable schizophrenia.
    Dale R; Longdon M; Seeman MV
    J Psychiatry Neurosci; 1994 Jul; 19(4):278-81. PubMed ID: 7918349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroleptic withdrawal in schizophrenic patients. A review of the literature.
    Gilbert PL; Harris MJ; McAdams LA; Jeste DV
    Arch Gen Psychiatry; 1995 Mar; 52(3):173-88. PubMed ID: 7872841
    [No Abstract]   [Full Text] [Related]  

  • 31. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroleptic dose reduction in persistently psychotic patients.
    Faraone SV; Green AI; Brown W; Yin P; Tsuang MT
    Hosp Community Psychiatry; 1989 Nov; 40(11):1193-5. PubMed ID: 2572532
    [No Abstract]   [Full Text] [Related]  

  • 33. Neuroleptic nonresponse and affective symptoms: a 2-year prospective study of schizophrenic outpatients.
    Faraone SV; Young AS; Brown WA
    Psychiatry Res; 1989 Jun; 28(3):315-21. PubMed ID: 2569751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroleptic dose reduction in older psychotic patients.
    Harris MJ; Heaton RK; Schalz A; Bailey A; Patterson TL
    Schizophr Res; 1997 Oct; 27(2-3):241-8. PubMed ID: 9416653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Sequence in prescribing neuroleptics: a therapeutic alternative in refractory schizophrenia?].
    Allouche G; Joober R; Vanelle JM; Brochier T; Olié JP
    Encephale; 1994; 20(6):777-80. PubMed ID: 7875112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose antipsychotic medication.
    Will D; Wrate RM; Bhate S; Taylor P; James T; Rothery D; Clark A
    Br J Psychiatry; 1994 Aug; 165(2):269-70. PubMed ID: 7953047
    [No Abstract]   [Full Text] [Related]  

  • 37. Symptomatology and electrodermal activity as predictors of neuroleptic response in young male schizophrenic inpatients.
    Lindström EM; Ohlund LS; Lindström LH; Ohman A
    Psychiatry Res; 1992 May; 42(2):145-58. PubMed ID: 1352902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe akathisia causing neuroleptic failure: an indication for lithium therapy in schizophrenia?
    Shalev A; Hermesh H; Munitz H
    Acta Psychiatr Scand; 1987 Dec; 76(6):715-8. PubMed ID: 2894745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acute dyskinesia as the cause of jaw dislocation].
    Kozian R; Kiszka T; Peter K; Kühne GE
    Psychiatr Prax; 1992 Jul; 19(4):119-21. PubMed ID: 1354880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.